"10.1371_journal.pone.0037485","plos one","2012-05-21T00:00:00Z","J√©r√¥me C√¥t√©; Veronica Bovenzi; Martin Savard; C√©l√©na Dubuc; Audrey Fortier; Witold Neugebauer; Luc Tremblay; Werner M√ºller-Esterl; Ana-Maria Tsanaclis; Martin Lepage; David Fortin; Fernand Gobeil","Department of Pharmacology, University Hospital, Frankfurt, Germany; Department of Nuclear Medicine and Radiobiology, University Hospital, Frankfurt, Germany; Institute for Biochemistry II, University Hospital, Frankfurt, Germany; Department of Pathology, Centre Hospitalier Universitaire de Sherbrooke, Universit√© de Sherbrooke, Sherbrooke, Quebec, Canada; Department of Surgery, Universit√© de Sherbrooke, Sherbrooke, Quebec, Canada; Institute of Pharmacology, Faculty of Medicine and Health Sciences, Universit√© de Sherbrooke, Sherbrooke, Quebec, Canada","Conceived and designed the experiments: JC FG. Performed the experiments: JC VB MS CD AF. Analyzed the data: JC MS LT AMT DF ML FG. Contributed reagents/materials/analysis tools: WN WME ML DF FG. Wrote the paper: JC VB MS FG.","DF, WN and FG from Universit√© de Sherbrooke hereby declare a duality of interest in view of their holding a patent made available to public in 2006 for the use of peptide kinin B1 receptor agonists in the treatment of brain cancer (Publication No. W0 2006/128293 A1). FG, DF and ML have received research funding from Tranzyme Pharma Inc. This company has no proprietary or financial interest in the outcome of the research. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","05","J√©r√¥me C√¥t√©","J√√C√√",12,TRUE,2,5,7,4,TRUE,TRUE,FALSE,0,NA,FALSE
